Clinical Trials Browser

Prostatic Neoplasms × pembrolizumab × 30 days × Clear all

NCT05766371 2026-04-17

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms